Our Partners
We are firmly committed to advancing the industry through pioneering science and reshaping the future of cancer treatment. For Ifebemtinib, we are actively pursuing global co-development and strategic business expansion opportunities, with a focus on its potential in combination with RAS pathway inhibitors and next-generation antibody-drug conjugates (ADCs). Building on deep insights into disease biology, we aim to maximize the synergistic potential of combination therapies to deliver better solutions for patients.
Furthermore, we remain open to diverse forms of R&D collaboration and licensing opportunities for innovative ADC programs, including those with first-in-class (FIC) targets. We look forward to partnering with global innovators to jointly drive breakthroughs in oncology.
Partner with Us
Leveraging an integrated drug discovery platform and a diversified product pipeline, we invite global partners to collaborate across multiple dimensions to advance drug development and jointly build an innovative biopharmaceutical ecosystem.
1. Clinical Development Collaboration
- Combination development of 1st‑generation FAKi (Ifebemtinib) / 2nd‑generation FAKi with RAS inhibitors ± immunotherapy (IO)
- Combination development of 1st‑generation FAKi (Ifebemtinib) / 2nd‑generation FAKi with antibody‑drug conjugates (ADCs) ± immunotherapy (IO)
2. Partnership & Licensing
- Multiple ADC, bispecific, and trispecific antibody programs have advanced to PCC and IND stages; global rights are available for partnership discussions
- The 1st‑generation FAKi is currently NDA‑ready, and the 2nd‑generation FAKi has entered the IND stage; both hold global rights and are open for collaboration
3. Drug Discovery Collaboration
- Biology‑Driven Smart Design：We have integrated five core platforms—translational medicine, antibody discovery, linker‑payload conjugation, developability optimization, and pharmacodynamic evaluation—to enable complementary external collaborations. Our goal is to shorten R&D timelines and establish a modular, streamlined innovative drug R&D system.
Contact：BD@InxMed.com
Combo with Inhibitors of RAS Pathway to Amplify the Clinical Responses
Our studies have demonstrated that Ifebemtinib exhibits synergistic effects with multiple RAS pathway inhibitors, including those targeting KRAS G12C, G12D, pan-KRAS, and multi-RAS, and also shows promising activity against tumors harboring NRAS and HRAS mutations. Building on a deep understanding of RAS signaling biology, the Ifebemtinib-RAS inhibitor combination we have designed shows superior therapeutic potential compared to other combinations, offering a compelling profile of high efficacy, favorable safety, and convenient oral administration. This regimen is positioned as a potentially transformative solution for RAS‑mutant tumors.
We are now actively seeking clinical partners to jointly advance the clinical development of Ifebemtinib in combination with various RAS inhibitors.
Combo with ADCs to Improve the Tumor Penetration and Boost Efficacy
Hard-to-treat cancers, such as pancreatic cancer, are characterized by a dense stroma. Stroma-rich tumors typically exhibit greater resistance to therapy. The high stromal content impedes the access of antibody-drug conjugates (ADCs) to tumor cells, thereby limiting their targeted efficacy. This dense stromal environment is largely driven by cancer-associated fibroblasts (CAFs). InxMed believes that reducing this fibroblast-mediated stromal barrier can enhance ADC effectiveness.
Tumor cells can transform normal fibroblasts into cancer-associated fibroblasts (CAFs), which are characterized by hyperactivated FAK signaling. These rapidly proliferating CAFs form a physical barrier that reduces the tumor uptake of large-molecule drugs, such as ADCs, conferring treatment resistance.
We discovered that targeting FAK with ifebemtinib can reduce this CAF-associated stromal barrier and enhance the tissue penetration of various ADCs, regardless of their target. In multiple preclinical studies, combination regimens containing ifebemtinib have demonstrated enhanced ADC efficacy.
QUICK LINKS
CONTACT US
Tel: +86 25-58251030
Email: office@inxmed.com
Office address: 73 Tanmi Road Block D-2, 3rd Floor Jiangbei New District, Nanjing
MESSAGE